Biomarkers of Gemtuzumab Ozogamicin Response ...
Type de document :
Compte-rendu et recension critique d'ouvrage
DOI :
PMID :
Titre :
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
Auteur(s) :
Fenwarth, Laurene [Auteur]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Fournier, Elise [Auteur]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cheok, Meyling [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Boyer, Thomas [Auteur]
CHU Amiens-Picardie
Gonzales, Fanny [Auteur]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Castaigne, Sylvie [Auteur]
Boissel, Nicolas [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Hopital Saint-Louis [AP-HP] [AP-HP]
Lambert, Juliette [Auteur]
Dombret, Herve [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Université Paris Diderot - Paris 7 [UPD7]
Preudhomme, Claude [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Duployez, Nicolas [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Fournier, Elise [Auteur]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cheok, Meyling [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Boyer, Thomas [Auteur]
CHU Amiens-Picardie
Gonzales, Fanny [Auteur]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Castaigne, Sylvie [Auteur]
Boissel, Nicolas [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Hopital Saint-Louis [AP-HP] [AP-HP]
Lambert, Juliette [Auteur]
Dombret, Herve [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Université Paris Diderot - Paris 7 [UPD7]
Preudhomme, Claude [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Duployez, Nicolas [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Titre de la revue :
International Journal of Molecular Sciences
Éditeur :
MDPI
Date de publication :
2020
ISSN :
1661-6596
Mot(s)-clé(s) en anglais :
CD33
FLT3
acute myeloid leukemia
biomarkers
gemtuzumab ozogamicin
therapy
FLT3
acute myeloid leukemia
biomarkers
gemtuzumab ozogamicin
therapy
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Gemtuzumab ozogamicin (GO, Mylotarg(R)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved ...
Lire la suite >Gemtuzumab ozogamicin (GO, Mylotarg(R)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials, led to the Food and Drug Administration (FDA) approval on 1 September 2017 in CD33-positive AML patients aged 2 years and older. Discrepancies in GO recipients outcome have raised significant efforts to characterize biomarkers predictive of GO response and have refined the subset of patients that may strongly benefit from GO. Among them, CD33 expression levels, favorable cytogenetics (t(8;21), inv(16)/t(16;16), t(15;17)) and molecular alterations, such asNPM1,FLT3-internal tandem duplications and other signaling mutations, represent well-known candidates. Additionally, in depth analyses including minimal residual disease monitoring, stemness expression (LSC17 score), mutations or single nucleotide polymorphisms in GO pathway genes (CD33,ABCB1) and molecular-derived scores, such as the recently set up CD33_PGx6_Score, represent promising markers to enhance GO response prediction and improve patient management.Lire moins >
Lire la suite >Gemtuzumab ozogamicin (GO, Mylotarg(R)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials, led to the Food and Drug Administration (FDA) approval on 1 September 2017 in CD33-positive AML patients aged 2 years and older. Discrepancies in GO recipients outcome have raised significant efforts to characterize biomarkers predictive of GO response and have refined the subset of patients that may strongly benefit from GO. Among them, CD33 expression levels, favorable cytogenetics (t(8;21), inv(16)/t(16;16), t(15;17)) and molecular alterations, such asNPM1,FLT3-internal tandem duplications and other signaling mutations, represent well-known candidates. Additionally, in depth analyses including minimal residual disease monitoring, stemness expression (LSC17 score), mutations or single nucleotide polymorphisms in GO pathway genes (CD33,ABCB1) and molecular-derived scores, such as the recently set up CD33_PGx6_Score, represent promising markers to enhance GO response prediction and improve patient management.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Projet ANR :
Collections :
Source :
Fichiers
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460695/pdf
- Accès libre
- Accéder au document
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- ijms-21-05626.pdf
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- ijms-21-05626.pdf
- Accès libre
- Accéder au document